A Long-Term Extension Study of RoActemra/Actemra (Tocilizumab) in Patients With Juvenile Idiopathic Arthritis Who Completed WA19977 Core Study
Information source: Hoffmann-La Roche
ClinicalTrials.gov processed this data on August 20, 2015 Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Juvenile Idiopathic Arthritis
Intervention: tocilizumab [RoActemra/Actemra] (Drug)
Phase: Phase 3
Status: Completed
Sponsored by: Hoffmann-La Roche Official(s) and/or principal investigator(s): Clinical Trials, Study Director, Affiliation: Hoffmann-La Roche
Summary
This long-term, open-label extension study will evaluate the safety of RoActemra/Actemra
(tocilizumab) in patients with polyarticular-course juvenile idiopathic arthritis who
completed the WA19977 core study. Patients aged 9-18 years with at least JIA ACR30 clinical
response to RoActemra/Actemra in the core study will be eligible to receive
RoActemra/Actemra 8 mg/kg intravenously every 4 weeks. Anticipated time on study treatment
is 104 weeks.
Clinical Details
Official title: Long-term, Interventional, Open Label Extension Study Evaluating the Safety of Tocilizumab Treatment in Patients With Polyarticular-course Juvenile Idiopathic Arthritis Who Completed the Global, Multinational Trial (WA19977)
Study design: Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Primary outcome: Safety: Incidence of adverse events
Secondary outcome: Response rates according to the American College of Rheumatology criteria for juvenile idiopathic arthritis (JIA ACR)Proportion of patients achieving inactive disease/clinical remission
Eligibility
Minimum age: 9 Years.
Maximum age: 18 Years.
Gender(s): Both.
Criteria:
Inclusion Criteria:
- Patients 9 to 18 years of age who completed visit 33 (week 104) of WA19977 study with
at least JIA ACR30 clinical response to RoActemra/Actemra relative to baseline in
WA19977, with no AEs, SAEs or conditions that lead to unacceptable risk of continued
treatment
- Scheduled to receive first RoActemra/Actemra infusion in this study between 4 and 6
weeks after the last IV infusion in the core study
- Females of child-bearing potential and males with female partners of child-bearing
potential must agree to use effective contraception as defined by protocol
Exclusion Criteria:
- Patients with, according to investigator judgment, not satisfactory benefit from
RoActemra/Actemra therapy within WA19977
- Treatment with any investigational agent since the last administration of study drug
in the core study WA19977 or current participation in another clinical trial except
WA19977
- Patient developed any other autoimmune rheumatic disease or overlap syndrome other
than the permitted polyarticular-course JIA subsets: rheumatoid factor positive or
negative JIA or extended oligoarticular JIA
- Patient is pregnant , lactating, or intending to become pregnant during the study and
up to 12 weeks after the last administration of study drug
- Any significant concomitant disease or medical or surgical condition
- History of significant allergic or infusion reactions to prior biologic therapy
- Known current active acute, subacute, chronic or history of recurrent infection;
patients suffering from ongoing active infections with Epstein Barr virus, herpes
zoster or recurrent history of urinary tract infection can be included after the
(acute) infection has been excluded or subsided
- Positive for latent tuberculosis (TB)
- Currently active asthma for which the patient has required the use of oral or
parenteral corticosteroids for >/= 2 weeks within 6 months prior to entering the
study
- Inadequate hepatic, renal or bone marrow function
Locations and Contacts
Bremen 28177, Germany
Frankfurt/Main 60316, Germany
Sankt Augustin 53757, Germany
Additional Information
Starting date: January 2012
Last updated: May 5, 2015
|